[{"orgOrder":0,"company":"NiKang Therapeutics","sponsor":"Cormorant Asset Management","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Series C Financing","leadProduct":"Undisclosed","moa":"HIF-2-alpha","graph1":"Oncology","graph2":"Preclinical","graph3":"NiKang Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"NiKang Therapeutics \/ Cormorant Asset Management","highestDevelopmentStatusID":"4","companyTruncated":"NiKang Therapeutics \/ Cormorant Asset Management"},{"orgOrder":0,"company":"NiKang Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"Atezolizumab","moa":"||HIF-2-alpha","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NiKang Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"NiKang Therapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"7","companyTruncated":"NiKang Therapeutics \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"NiKang Therapeutics","sponsor":"Hansoh Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"NKT2152","moa":"HIF-2-alpha","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NiKang Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"NiKang Therapeutics \/ Hansoh Pharma","highestDevelopmentStatusID":"7","companyTruncated":"NiKang Therapeutics \/ Hansoh Pharma"},{"orgOrder":0,"company":"NiKang Therapeutics","sponsor":"Hansoh Pharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"NKT-1992","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"NiKang Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NiKang Therapeutics \/ Hansoh Pharma","highestDevelopmentStatusID":"4","companyTruncated":"NiKang Therapeutics \/ Hansoh Pharma"},{"orgOrder":0,"company":"NiKang Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"NKT3447","moa":"CDK2","graph1":"Oncology","graph2":"Phase I","graph3":"NiKang Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"NiKang Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"NiKang Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NiKang Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"NKT2152","moa":"HIF-2-alpha","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NiKang Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"NiKang Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"NiKang Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NiKang Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||HIF-2-alpha","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NiKang Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"NiKang Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"NiKang Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NiKang Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"NKT3964","moa":"CDK2","graph1":"Oncology","graph2":"Phase I","graph3":"NiKang Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"NiKang Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"NiKang Therapeutics \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals by NiKang Therapeutics

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Peptide Therapy Summit
                          Not Confirmed
                          Peptide Therapy Summit
                          Not Confirmed

                          Details : NKT3964, a first-in-class, highly potent and selective, orally bioavailable CDK2 degrader, which is being evaluated for the treatment of solid tumors.

                          Product Name : NKT3964

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          March 10, 2025

                          Lead Product(s) : NKT3964

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          Peptide Therapy Summit
                          Not Confirmed
                          Peptide Therapy Summit
                          Not Confirmed

                          Details : NKT2152, a highly potent, selective & orally bioavailable small molecule HIF2α inhibitor, in combination with standard-of-care in the first-line treatment of patients with advanced or metastatic HCC.

                          Product Name : NKT2152

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          January 21, 2025

                          Lead Product(s) : NKT2152,Atezolizumab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          Peptide Therapy Summit
                          Not Confirmed
                          Peptide Therapy Summit
                          Not Confirmed

                          Details : NKT3447 is an oral, selective inhibitor of CDK2 which reduces cyclin E expression. It is being evaluated for the treatment of patients with cancers driven by cyclin E amplification or overexpression.

                          Product Name : NKT3447

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          April 15, 2024

                          Lead Product(s) : NKT3447

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          Peptide Therapy Summit
                          Not Confirmed
                          Peptide Therapy Summit
                          Not Confirmed

                          Details : The collaboration aims to evaluate NKT2152, a small molecule that inhibits hypoxia inducible factor 2α (HIF2α), in combination with standard-of-care Tecentriq (atezolizumab) and Avastin (bevacizumab) in first-line treatment of unresectable/advanced hep...

                          Product Name : NKT2152

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          August 12, 2023

                          Lead Product(s) : NKT2152,Atezolizumab

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : F. Hoffmann-La Roche

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          05

                          Peptide Therapy Summit
                          Not Confirmed
                          Peptide Therapy Summit
                          Not Confirmed

                          Details : The anti-tumor effect observed in several xenograft models suggests NKT2152, a HIF2α inhibitor, may have broader activity in other solid tumors beyond ccRCC that lack a VHL gene deficiency.

                          Product Name : NKT2152

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          August 04, 2022

                          Lead Product(s) : NKT2152

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          Peptide Therapy Summit
                          Not Confirmed
                          Peptide Therapy Summit
                          Not Confirmed

                          Details : Under the terms of the agreement, Hansoh will be responsible for all the development costs for NKT2152 in Greater China and will receive the exclusive rights to develop and commercialize NKT2152 in the region.

                          Product Name : NKT2152

                          Product Type : Other Small Molecule

                          Upfront Cash : $15.0 million

                          March 05, 2022

                          Lead Product(s) : NKT2152

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Hansoh Pharma

                          Deal Size : $218.0 million

                          Deal Type : Collaboration

                          blank

                          07

                          Peptide Therapy Summit
                          Not Confirmed
                          Peptide Therapy Summit
                          Not Confirmed

                          Details : Proceeds will be used to advance the company’s lead drug candidates into the clinic, expand the pipeline and fund internal drug discovery programs.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          May 26, 2021

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : Cormorant Asset Management

                          Deal Size : $200.0 million

                          Deal Type : Series C Financing

                          blank

                          08

                          Peptide Therapy Summit
                          Not Confirmed
                          Peptide Therapy Summit
                          Not Confirmed

                          Details : Under the terms of the collaboration, Hansoh Pharma will be responsible for leading development and commercialization of NKT-1992 in Greater China.

                          Product Name : NKT-1992

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          April 23, 2020

                          Lead Product(s) : NKT-1992

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Preclinical

                          Sponsor : Hansoh Pharma

                          Deal Size : $100.0 million

                          Deal Type : Collaboration

                          blank